NCT07437547 (BPC-HAMSTR) is a Phase 2 clinical trial of Pentadecapeptide BPC 157 in Hamstring Muscle Strain, sponsored by Hudson Biotech.

Who is sponsoring NCT07437547?

NCT07437547 is sponsored by Hudson Biotech.

What drugs are being tested in NCT07437547?

Interventions in NCT07437547: Pentadecapeptide BPC 157, Placebo.

What condition does NCT07437547 study?

NCT07437547 studies Hamstring Muscle Strain, Skeletal Muscle Injury.

Is NCT07437547 still recruiting?

NCT07437547 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT07437547: BPC-HAMSTR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BPC 157 for Acute Hamstring Muscle Strain Repair

Recruiting now Phase 2 Last updated 27 February 2026

What this trial tests

Phase 2 trial testing Pentadecapeptide BPC 157 in Hamstring Muscle Strain in 120 participants. Currently enrolling.

Timeline

2 February 2026

Primary endpoint
14 February 2027

17 February 2028

Quick facts

Lead sponsor	Hudson Biotech
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	120
Start date	2 February 2026
Primary completion	14 February 2027
Estimated completion	17 February 2028
Sites	1 location across China

Drugs / interventions tested

Pentadecapeptide BPC 157 — full drug profile →
Placebo

Conditions studied

Hamstring Muscle Strain — all drugs for Hamstring Muscle Strain →
Skeletal Muscle Injury — all drugs for Skeletal Muscle Injury →

Sponsor

Hudson Biotech — full company profile →

Who can join

Adults 18 to 45, any sex, with Hamstring Muscle Strain or Skeletal Muscle Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hudson Biotech trials

Trials by the same sponsor.

NCT07467447 — Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight · Phase 2 · recruiting
NCT07487363 — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD · Phase 1, PHASE2 · recruiting
NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity · Phase 2 · recruiting
NCT07437560 — Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo · Phase 2 · recruiting
NCT07437586 — Topical GHK-Cu Gel for Acute Skin Wound Healing · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07437547 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hudson Biotech
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07437547.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing